NCT06144086View on ClinicalTrials.gov

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia (OP-724-H201)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Liver Cirrhosis
Interventions
DRUG

Foscenvivint

Administered by intravenous (IV) infusion over 3-4 hours

Trial Locations (3)

060-8648

Hokkaido University Hospital, Sapporo

540-0006

National Hospital Organization Osaka National Hospital, Osaka

113-8677

Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Kiminori Kimura, MD

OTHER